



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 21, 2023

Michael Mano  
Senior Vice President and General Counsel  
Karyopharm Therapeutics Inc.  
85 Wells Avenue, 2nd Floor  
Newton, MA 02459

**Re: Karyopharm Therapeutics Inc.**  
**Registration Statement on Form S-3**  
**Filed February 17, 2023**  
**File No. 333-269846**

Dear Michael Mano:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Arzhang Navai at 202-551-4676 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Craig Hilts